Personalization in medicine means a new approach to diagnostics and therapy, using the individual characteristics of each patient. Thanks to DNA analysis and innovative technologies, treatment is becoming more effective and safer. Personalized medicine is a chance for higher quality of life and prevention tailored to our needs.
Table of Contents
- What is personalized medicine?
- Precision medicine in oncology
- The role of DNA in personalized therapy
- New standards in personalized treatment
- Challenges for the future of precision medicine
- The importance of personalization for patients
What is personalized medicine?
Personalized medicine, also known as precision medicine, is an approach to diagnosing, preventing, and treating diseases in which the key role is played by the patient’s individual traits: their genetic material (DNA), lifestyle, environment, and even the composition of the gut microbiome. Instead of treating all patients with the same disease identically, personalized medicine aims to create a “tailor-made” therapeutic plan that takes into account the unique biological conditions of a given person. In the classical approach, treatment protocols are based on averaged clinical trial results—the doctor knows that, for example, a certain drug statistically helps most patients with a given diagnosis. In personalized medicine, the goal is to predict how an individual patient will respond, even before administering a drug or implementing a medical procedure. This radically changes clinical decision-making. The foundation here is knowledge from genetics and genomics—thanks to DNA sequencing, it is possible to detect mutations, polymorphisms, and other genetic variants that affect the risk of a given disease or the response to treatment. Analyses focus on, among other things, genes related to drug metabolism (pharmacogenomics), genes predisposing to cancers, cardiovascular diseases, or neurodegenerative diseases. However, personalized medicine is not limited to genes alone—it also includes analysis of the proteome (proteins), metabolome (metabolites), and increasingly, data from wearable devices that monitor a patient’s vital signs in real time. The collected information is integrated using advanced bioinformatics tools and artificial intelligence algorithms, enabling the creation of predictive models for disease progression, complication risk, and the effectiveness of particular therapies. Personalized medicine also involves a different way of thinking about prevention. Instead of universal recommendations like “more exercise” or “less fat in the diet,” it becomes possible to develop personalized disease prevention programs based on an individual risk profile—a patient may receive, for example, a recommendation to start screening earlier if their genes suggest a greater likelihood of developing a certain cancer. This also includes lifestyle modification and supplementation tailored to the actual needs of the body rather than general population norms, increasing the chance that preventive measures are truly effective. In practice, personalized medicine is most evident in oncology, where molecular analysis of a tumor allows for the selection of targeted drugs only for those patients with specific mutations, such as EGFR, ALK, or BRAF. Similar approaches are developing in cardiology, rheumatology, diabetology, and psychiatry, where genetic factors influencing drug response are increasingly taken into account to avoid the laborious and risky “trial and error” method. Personalization also applies to dosage—knowledge of how quickly a patient metabolizes drugs allows for reducing the risk of adverse effects and increasing therapeutic success. An important element of personalized medicine is also the active role of the patient, who becomes a partner in the decision-making process, as they understand their health risk and receive personal data in an accessible, comprehensible form. With increased availability and decreasing costs of genetic testing, this concept is gradually entering clinical practice not only in large research centers, but also in modern specialist clinics and primary healthcare, redefining the standard of medical care.
It is crucial to understand that personalized medicine is not a single treatment or test, but a whole paradigm of healthcare based on patient data and continuous analysis of that data. In this approach, the patient is no longer a “textbook case,” but a complex set of biological, clinical, and environmental information that can be continually updated. The physician can use electronic medical records linked with genetic test results, imaging, laboratory data, and even health apps and devices monitoring sleep, physical activity, or heart rhythm. Compiling this information over time enables not only tailored therapy at a given moment, but also dynamic modification as the patient’s health changes or as new scientific evidence arises. Personalized medicine is, therefore, a continuous process—the patient’s profile evolves, and so does the treatment strategy. What’s notable is that this approach emphasizes precise definition of disease subtypes that were previously treated as homogeneous. Molecular research reveals that, for example, “breast cancer” is in reality a group of different illnesses with varying genetic backgrounds, courses, and responses to treatment, requiring a diversity of therapeutic routes. Similarly, for depression, asthma, or diabetes, personalized medicine aims to break down large, generic diagnostic categories into more precise phenotypes and endotypes. From a healthcare system perspective, this means moving from reactive medicine, which mostly intervenes when a disease is established, to proactive and predictive medicine that tries to foresee health issues before they arise. However, this requires the development of digital infrastructure, molecular diagnostics labs, standards for collecting and protecting medical data, and proper training of physicians and healthcare staff in interpreting complex genetic test results. Despite these challenges, personalized medicine is increasingly becoming the foundation of modern healthcare, where not only clinical effectiveness but also safety, comfort, and individual patient needs count, considered over the long term of the patient’s life.
Precision medicine in oncology
Precision medicine in oncology is currently one of the fastest-developing areas of personalized medicine, as cancers are uniquely complex and individualized diseases. The traditional approach, in which patients with the same type of cancer receive similar treatment regimens, is increasingly being replaced by therapies adapted to the molecular profile of the tumor. The key element in this process is genetic and molecular diagnostics—analyzing cancer cell DNA, gene expression, proteins, and metabolites to discover driver mutations that promote disease development and potential therapeutic targets. In practice, the diagnosis “lung cancer” or “breast cancer” is no longer sufficient—the biological subtype matters, defined by the presence of EGFR, ALK, ROS1, BRAF, HER2 mutations, or specific hormone receptors. In oncology, precision medicine also uses advanced imaging techniques and so-called liquid biopsy—analyzing tumor genetic material circulating in the blood (ctDNA)—which makes it possible to monitor treatment effectiveness and detect early relapses without invasive biopsies. Increasingly important are multi-gene panels and whole-exome or whole-genome sequencing that allow for testing dozens or hundreds of cancer-related genes at once, making it possible to select targeted therapy even in rare and atypical cases. Moreover, precision oncology considers pharmacogenomics—individual differences in drug metabolism—that help tailor optimal doses of cytostatics or oral drugs and minimize the risk of serious adverse effects such as damage to the heart, kidneys, or bone marrow.
The revolution in cancer treatment is particularly driven by the development of molecularly targeted therapies and immunotherapies, which are a direct result of personalized approaches. Targeted therapies affect specific signaling pathways in cancer cells, blocking proteins encoded by mutated genes, such as BCR-ABL in chronic myeloid leukemia or BRAF V600E in melanoma. As a result, they act more selectively than classic chemotherapy, which also harms healthy, rapidly dividing cells. Immunotherapy, including checkpoint inhibitors (e.g., anti-PD-1, PD-L1, CTLA-4 drugs), aims to unleash the body’s immune response against tumor cells. The effectiveness of such drugs is closely related to biomarkers, such as PD-L1 expression, tumor mutation burden (TMB), or microsatellite instability (MSI-H), so specialist testing is essential before therapeutic decisions. In clinical practice, “basket” and “umbrella” trials are increasingly appearing—basket studies group patients according to the presence of specific molecular biomarkers regardless of tumor location, while umbrella studies test different targeted therapies within one cancer type, but with various genetic profiles. Implementing precision medicine in routine oncology practice requires close cooperation of multidisciplinary teams—oncologists, clinical geneticists, pathologists, bioinformaticians, and pharmacologists—as well as appropriate lab and digital infrastructure for storing and analyzing so-called oncology big data. This enables not only precise treatment selection, but also dynamic modification during therapy, e.g., if drug resistance arises due to new mutations. Despite challenges such as the cost of testing, drug availability, or the need for uniform guidelines, precision medicine in oncology is already significantly increasing the proportion of patients who respond to therapy, extends survival times, and increasingly allows good quality of life even with cancer, shifting care from a reactive to a highly planned model based on predicting tumor biological behavior.
The role of DNA in personalized therapy
DNA is the foundation of personalized medicine, as it provides the unique “instruction code” for bodily functioning, influencing disease occurrence, drug response, and the pace of regeneration and aging processes. In the traditional treatment model, all patients with the same diagnosis receive similar therapies; genome analysis allows us to move away from this averaged approach and design treatments fit to individual biological characteristics. DNA sequencing is the central tool—ranging from single gene testing, through multi-gene panels, to whole-exome sequencing (WES) and whole-genome sequencing (WGS). These tests identify genetic variants affecting disease risk, course, and the effectiveness and safety of specific therapies. This is especially significant in oncology, where somatic mutations in cancer cells (e.g., in the EGFR, BRAF, ALK, HER2 genes) determine the choice of targeted drugs—but DNA’s role is equally important in cardiology, endocrinology, neurology, psychiatry, and general pharmacology. Knowing the individual genetic profile allows us to predict which patient will benefit from a drug, and who may suffer a severe adverse reaction, minimizing complications and unnecessary expenses associated with ineffective therapy.
Pharmacogenomics—studying the effect of genes on drug metabolism, their concentrations in blood, and action at target sites—plays an ever greater role in personalized therapy. Differences in genes encoding cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP3A4, etc.), drug transporters (e.g., P-gp/MDR1), or pharmacological receptors mean the same dose of the same drug can have vastly different effects in different people—from no effect to severe toxicity. In the clinic, examples of using DNA information include tailoring anticoagulation (e.g. warfarin, analyzing CYP2C9 and VKORC1 genes), antidepressants/antipsychotics (influenced by CYP2D6 and CYP2C19), and chemotherapy (e.g., fluorouracil, capecitabine, thiopurines, where DPYD and TPMT mutations can cause life-threatening complications). Thanks to pharmacogenomic tests, doctors can select the right dose from the start or pick another drug altogether, reducing the “trial and error” method. In personalized medicine, DNA serves not only for optimizing existing therapies, but also for identifying new molecular targets and designing drugs fitted to specific pathway disturbances. Analysis of cancer genome sequences may reveal “driver” mutations that make a cancer cell vulnerable to a particular inhibitor or monoclonal antibody; similarly, for rare diseases, finding pathogenic variants enables gene therapy or exon-skipping approaches to fix or bypass the genetic defect. Genome editing technologies such as CRISPR/Cas9 and newer base or prime editing systems offer prospects of directly modifying DNA sequences in patient cells. Though these require careful safety evaluation (off-target effects, mosaicism, long-term consequences), they signal a move towards causal, not only symptomatic, therapies. DNA is also a central element of personalized prevention: panel tests for BRCA1/2 mutations, genes linked to familial colon polyposis, cardiomyopathies, or arrhythmias enable more intensive monitoring, earlier screening, prophylactic surgery, or lifestyle changes for higher-risk people even before symptoms appear. Importantly, interpreting DNA results requires advanced bioinformatics tools, genetic variant databases, and teamwork from clinical geneticists, oncologists, cardiologists, and other specialists. This multidisciplinary ecosystem ensures that raw sequencing data becomes clinical information, translating into specific therapeutic and preventive decisions, and that the patient is cared for with their individual genetic code as the foundation of personalized therapy.
New standards in personalized treatment
Until recently the domain of select research centers, personalized medicine is now increasingly setting clinical care standards. The starting point is already evolving: classic algorithms based solely on disease diagnosis are being replaced with diagnostic-therapeutic pathways that consider molecular profile, environmental factors, lifestyle, patient preferences, and individual health history. More scientific society guidelines—especially in oncology, cardiology, or rheumatology—require or strongly recommend genetic tests, biomarker assays, or pharmacogenomic testing prior to treatment decisions. A new standard is the creation of multidisciplinary teams (tumor board, heart team, pharmacogenomics board), with oncologists, clinical geneticists, bioinformaticians, clinical pharmacists, psychologists, and dieticians jointly analyzing the patient’s data to create the optimal treatment plan. Still, the patient remains central—their role shifts from a passive beneficiary to an active partner who participates in treatment choices, understands potential benefits and risks, and has genuine influence on decisions about prevention, monitoring, and therapy modification. Digitalization of the process is also standardizing: imaging, lab, and genomic data, plus wearables (monitoring heart rate, sleep, activity, or glucose levels), are integrated into a single IT ecosystem. Clinical Decision Support Systems (CDSS), based on AI and machine learning, analyze this information, match it with current guidelines and knowledge bases, and suggest the doctor the most appropriate therapies. Thus, medical decisions are no longer based solely on individual experience, but on analysis of huge datasets generating conclusions suited to the individual patient. At the same time, requirements for quality and validation of diagnostic tests are rising—accredited labs, standardized gene panels, and clear result interpretation thresholds are becoming norms to minimize overinterpretation or costly misclassification for targeted therapies.
New standards in personalized treatment also include how therapy is conducted over time, not just at initiation. Approaches like “treat-to-target” and “monitor-and-adjust” are being augmented with continuous, often remote, assessment of therapeutic efficacy and early detection of unwanted responses. In practice, this means using tools such as fluid biopsies to monitor circulating tumor DNA, patient-reported symptom apps in real-time, or “remote patient monitoring” programs where vital signs are automatically relayed to hospital systems. Dynamic modification of therapy—changing dose, drug, or the whole strategy—according to current molecular images and organism response, not only fixed protocols, is becoming standard. Improved documentation and information sharing is another key development: patients have greater access to their own genomic data and personalized reports that clearly explain the meaning and daily health implications of detected genetic variants. Ethical and regulatory standards are being developed in parallel—clear explanations about the capabilities and limitations of genetic tests, consent procedures for using genomic data in research, and security guarantee in accordance with GDPR and national law are all required. “Equity in precision medicine”—ensuring equal access to personalized treatments regardless of residence, socio-economic status, or education—is increasingly discussed. Thus, new standards mean not only implementing the latest sequencing or AI technologies, but also developing reference networks, reimbursement programs for selected genome tests, and broad-based education for physicians and patients. All these elements—from molecular diagnostics standardization, through digital clinical decision support, to ethical and organizational frameworks—constitute a new treatment paradigm where personalization is not an add-on to classic medicine, but the required reference point for planning every therapy.
Challenges for the future of precision medicine
Although offering enormous therapeutic potential, precision medicine faces a range of challenges that will determine the pace and scale of clinical adoption. One key issue is unequal access to advanced diagnostic and therapeutic technologies, resulting from economic disparities between countries and internal inequalities within healthcare systems. Whole-genome sequencing, multi-gene tests, and advanced bioinformatics still require costly, specialized infrastructure and highly trained staff. Many district hospitals or smaller clinics remain unable to participate fully in personalized medicine, threatening the emergence of “two-speed medicine”—one for major reference centers and another relying on classic algorithms for the rest of society. There is also the matter of funding targeted therapies, immunotherapies, or gene therapies, with per-patient costs much higher than traditional treatments. Payers—public and private insurers—face the dilemma of how to evaluate the cost-effectiveness of therapies that may be very effective for a small group, but significantly strain budgets. New reimbursement models are required, for example, value-based healthcare, performance payments, or risk-sharing between drug producers and payers. Standardizing diagnostic procedures is another challenge—different labs using varied panels and analysis methods may produce incomparable results, hindering unified guidelines and care paths. Without united standards for molecular testing quality, biomarker validation, and interoperable data formats, precision medicine risks information chaos and divergent clinical decisions. Another area is data management—both technical and legal. Personalized medicine generates vast amounts of “omics” data (genomics, transcriptomics, proteomics, metabolomics), clinical records, and wearable/app health information. Secure storage, anonymization, integration with electronic medical records, and efficient use by AI algorithms require cloud investment, cybersecurity, and system interoperability. In many countries, the obstacle is not just the lack of IT infrastructure but data fragmentation—scatter among different providers, no unified disease registries, and inconsistent data formats, making it difficult to create large, representative databases vital for predictive algorithm development.
In parallel to technological and economic challenges, growing ethical and regulatory dilemmas concern the sensitivity of genetic data. Issues arise regarding informed consent: does the patient truly understand the consequences of genome sequencing, such as incidental findings (e.g., variants that increase risk for unrelated diseases) and the potential impact on their family? Implementing precision medicine requires legal frameworks for storing, sharing, and re-using genomic data—balancing research and AI training needs with patient privacy and the prevention of genetic discrimination in employment or insurance. Regulations must keep pace with innovation, which is not easy as technologies like CRISPR gene editing, CAR-T cell therapies, or advanced tumor profiling emerge faster than legislation. Additionally, a frequently underestimated challenge is preparing medical staff to work in a data- and algorithm-driven environment. Doctors, nurses, lab diagnosticians, and pharmacists need new competencies—from bioinformatics basics and genetic test interpretation to critical assessment of AI-generated recommendations. Without proper training, professionals may either overtrust the “black box” of algorithms or, conversely, reject valuable digital tools. Patient engagement in decision making and genomics education is also essential—so individuals can make conscious use of personalized treatment benefits and understand the limitations. Overlaying all these issues is the question of therapeutic liability in data-driven medicine: who is responsible if an algorithm’s recommendation proves ineffective or harmful—the doctor, the software creator, or the institution that implemented it? Resolving these dilemmas, together with ensuring transparency in AI operation, will be key for regulators, scientists, and clinicians, should precision medicine become a durable and trusted pillar of the health system.
The importance of personalization for patients
Personalized medicine changes the patient experience on many levels—from diagnosis to treatment selection, long-term health monitoring, and prevention. The key benefit is the sense that the patient is no longer a “clinical case” subject to general protocols, but a partner in therapy, with individual needs, preferences, and predispositions genuinely considered. Thanks to genetic testing, biomarker analysis, lifestyle, and medical history, the doctor can propose a much more effective therapy from the first line of treatment. This leads to shorter remission times, fewer failed therapies, and less frustration from “trial and error” treatment. Patients with chronic conditions such as cancer, diabetes, autoimmune disorders, or depression gain access to treatment plans customized to their biology and reality—with optimized dosing, adverse effect monitoring, and the ability to continually adjust therapy in response to changing conditions. This supports greater therapy effectiveness, as seen in hard endpoints like survival and disease exacerbations, but also in quality of life—the ability to work, maintain social relationships, function within the family, and fulfill personal plans. Another key dimension of personalization is patient safety. Pharmacogenomics allows prediction of dangerous drug reactions before they occur, which is crucial in chemotherapy, anticoagulation, psychiatric treatment, or use of powerful painkillers. This can avoid serious complications, hospitalizations, and even life-threatening events. In addition, precisely matching treatment often enables lower effective doses, reducing toxicity. For many, the difference between a standard and a personalized regimen means fewer hospital days, less severe side effects, no need to quit work, or curtail family activity. Thanks to remote monitoring technologies and health apps, patients now receive more transparent online information, the ability to report symptoms in real time, and contact with the therapeutic team—strengthening safety and empowerment, and allowing quick reactions to worrying changes in their condition.
Personalization in medicine is also hugely significant psychologically and socially. Patients who see that their treatment is based on detailed analysis of DNA, biomarkers, living conditions, and preferences are more likely to trust the doctor and adhere to recommendations. The feeling that therapy is “tailor-made,” not imposed according to an anonymous scheme, reduces fear and uncertainty often associated with diagnosis of a severe or chronic disease. Transparent explanation of why a drug or regimen was selected specifically for this person helps the patient understand treatment mechanisms and engage in therapy—by changing lifestyle, carrying out regular follow-up tests, or monitoring health parameters at home. Personalization also facilitates earlier detection of disease in individuals with elevated genetic or environmental risk. Patients informed of predispositions (e.g., for breast cancer, Alzheimer’s, cardiovascular disease) can plan with their doctor more intensive screening, implement justified drug prevention, and modify their diet, activity, sleep, and stress habits. For many, the ability to “get ahead” of illness before it manifests is personalized medicine’s greatest value. At the same time, patients have increasing control over their health data—now often accessible in digital form, available for consultation with different specialists, and under their control for sharing. Socially, this represents a gradual shift from a passive care model, in which the patient “follows the doctor’s decisions,” to a partnership model, where the treatment and prevention strategy is developed collaboratively. In countries with broad implementation of personalized medicine, outcomes improve and patient satisfaction with the health system rises—supporting better resource use and more rational medical service consumption. For patients, this means fewer unnecessary tests, fewer unnecessary visits, a clearer therapeutic pathway, and assurance that their time, health, and data are treated with due care and respect.
Summary
Personalized medicine is the future where tailor-made treatment becomes the standard. Thanks to DNA analysis and new therapy standards, patients receive more precise and effective medical solutions. While challenges are numerous, the opportunities personalization offers for oncology and other medical disciplines are enormous. The key aspect is individualized care, delivering patients the best possible outcomes and improving their quality of life and health.
